Aficamten and device-guideline advances reshape cardiology

A randomized Phase 3 trial reportedly found that aficamten improved exercise capacity, quality of life, and clinical outcomes in nonobstructive hypertrophic cardiomyopathy. Updated European heart-failure guidance reportedly strengthened support for selected HeartMate 3 and CardioMEMS patients, but regulatory review, long-term safety, independent guideline verification, and real-world outcomes remain important.